GlassScriptPhysician profile
Maty Yakoby
NPI 1780065250
$468.93
in general payments reported to CMS, 2019-2025
13 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.35 · 2024: $317 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.37 | 2024 | Trelegy Ellipta |
| Lilly USA, LLC | $56.72 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $50.87 | 2024 | Farxiga, Airsupra |
| Medtronic, INC. | $50.52 | 2024 | Minimed 780g |
| Novo Nordisk INC | $47.76 | 2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $42.69 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $35.10 | 2024 | Repatha |
| Axsome Therapeutics, INC. | $22.66 | 2025 | Auvelity |
| Insulet Corporation | $22.18 | 2024 | Omnipod |
| Boston Scientific Corporation | $21.20 | 2024 | Lux-Dx Insertable Cardiac Monitor |
| Madrigal Pharmaceuticals | $18.20 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $17.20 | 2024 | Voquezna |
| Intra-Sana Laboratories | $16.46 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maty Yakoby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.